Targeting Inflammation in Treated HIV, version 3.0

Peter W. Hunt, MD
Professor of Medicine, Division of Experimental Medicine, UCSF
Co-Director of Basic/Translational Sciences, Center for AIDS Research
San Francisco, CA

Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2024. All rights reserved.



CME VIDEOTop of page

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Survey

About the Presenter:Top of page

Peter Hunt is a Professor of Medicine in the Division of Experimental Medicine at UCSF and Co-Director of the UCSF-Bay Area Center for AIDS Research for Basic and Translational Science. His primary research focus is on the inflammatory consequences of HIV infection. His translational research program seeks to understand the causes and consequences of persistent immune activation and its impact on aging-associated multi-morbidity and mortality in treated HIV infection, as well as its impact on HIV persistence. He also conducts clinical trials of novel immune-based interventions designed to decrease immune activation and recently completed a term as Chair of the Inflammation Committee of the AIDS Clinical Trials Group (ACTG). Dr. Hunt led a translational research program in Mbarara, Uganda, focused on the determinants of immune recovery during suppressive antiretroviral therapy in that setting and helped develop a large mucosal immunology program at Zuckerberg San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection. In July, 2016, he also started a laboratory to better characterize the immune defects that drive morbidity and mortality in treated HIV, with a specific focus on the role of CMV co-infection as an important mediator. He leads a large clinical trial of the anti-CMV drug letermovir in the ACTG, exploring its impact not just on systemic inflammation, but also on cardiometabolic and neurocognitive outcomes. He has also recently extended his CMV work to address its impact on COVID-19 pathogenesis.

Learning Objectives: Top of page

At the completion of this educational activity learners will:
1. Understand how comparing the inflammatory predictors of disease in people with treated HIV to those in the general population can help us identify interventional targets that are particularly relevant for people with HIV.
2. Appreciate how genetics studies can help us understand what inflammatory pathways are most relevant in contributing to disease risk in people with treated HIV.
3. Be aware of the many ways asymptomatic CMV appears to affect the immune system in people with treated HIV.

CME Information:Top of page


This CME activity has approved for AMA PRA Category 1 Credit™ for November 19, 2024, as a live activity. This activity will also be available as an enduring activity from November 26, 2024, through November 18, 2027.

The target audience is all physicians, NPs and PAs involved in or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement:Top of page

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.

- Dr. James F. Braun (Course Director/Program Planner) has no relevant financial relationships to disclose.
- Dr. Joseph P. McGowan, MD (Moderator) has no relevant financial relationships to disclose.
- Dr. Peter W. Hunt, MD (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Consultant to Merck and ViiV; Honorarium from Gilead and ViiV; Research Grant from Gilead; Drug Donation from Merck. Dr. Hunt submitted his slides in advance for adequate peer review and supported his presentation and clinical recommendations with the best available evidence from the medical literature. All relevant financial relationships have been mitigated.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from Gilead Sciences and ViiV Healthcare and by a generous charitable contribution from Northwell Health Center for AIDS Research & Treatment.

You must be logged in to post a comment. Login | Register